35 results about "Serum iron tests" patented technology

Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.

Disclosed herein are compounds, compositions and methods for modulating the expression of hepcidin in a cell, tissue or animal or preventing, ameliorating or treating anemia. Also provided are methods for prevention, amelioration or treatment of anemia, and for increasing red blood cell count in an animal. Also provided are methods for the prevention, amelioration and/or treatment of low serum iron levels, low red blood cell count and other clinical endpoints of anemia in an animal. These methods may be achieved by administration of compounds or compositions including antisense compounds targeted to a nucleic acid that expresses hepcidin polypeptide combined with an erythropoiesis stimulating agent.

The invention discloses a medicine application of iron liposome. By taking animals with chronic inflammation as a model, a brand-new medicine which treats anaemia caused by the dysfunction of the iron absorption of the small intestine to relevant protein molecules and takes the iron liposome as an effective component is provided. The invention takes white rats with inflammatory anaemia as a model, adopts an oral stomach infusion method and compares the curative effect of the iron liposome for the anaemia with that of a chalybeate which is not enveloped by the liposome, and the iron liposome can obviously enhance the levels of the hemoglobin, the blood cell volume, the serum iron and the saturation rate of the transferrin of an organism in a short time, can act as a very good curative effect to the inflammatory anaemia and can not cause injuries to the health of the organism. The iron liposome is obviously superior to the traditional iron-replenished preparation. The invention can be used for treating the anaemia caused by the dysfunction of the iron absorption of the small intestine to the protein molecules because of various known or unknown reasons. Various tablets, capsules, dripping pills, oral liquid and food additives which are taken orally and contain the iron liposome are prepared.

The present inventors have found that a siderophore-iron (III) ion chelate complex is highly absorbed in the body; significantly increases the blood hemoglobin concentration, the serum iron concentration and the concentration of iron stored in the liver; and causes no adverse effects on the body. On the basis of these findings, the present inventors provide iron supplementing agents, agents for the prevention or treatment of iron defeciency anemia, food additives and food compositions, each of which contains a siderophore and iron (III) ions, preferably in the form of a chelate complex.

The invention belongs to the technical field of biology and belongs to a total iron binding force detection kit, in particular, a preparation method of a total iron binding force detection kit. The preparation method involves the preparation of a reagent R1 and the preparation of a reagent R2; a solution preparation tank is arranged on a magnetic stirrer; a solution is made to keep a medium-speedrotating state; a Tris buffer solution, ferrous azine, ascorbic acid and a second buffer solution are added when stirring is performed; stirring is performed for 30 minutes until the materials are completely dissolved, and the solution is clear and transparent and has no precipitate at the bottom of the solution preparation tank; and volume fixing is carried out, so that the volume of the solutioncan be a final volume. According to the detection kit, a spectrophotometric method is adopted to detect a total iron binding force with the ferrous azine used as a substrate; serum iron combined withtransferring, in an acidic medium, is dissociated from the transferrin; and the serum iron is reduced into Fe <2+> by a reducing agent, the Fe <2+> and the ferrous azine generate a purplish red compound; a absorbance value at 562nm is detected by a spectrophotometer, so that total iron content in serum and plasma samples can be detected; and the linear range of the kit can reach 50-400 micromole/L.

The invention discloses a thiazolidone compound, wherein a chemical structure of the thiazolidone compound is shown in a general form (I). The invention also discloses application of the thiazolidone compound in preparation of a medicine used for treating thalassemia. Experiments prove that the thiazolidone compound can be used for effectively stimulating expression of hepcidin in cells under the condition that concentration is 10mu M, can be still used for effectively inducing expression of hepcidin in liver when being exposed for 6 hours, 24 hours and 48 hours respectively at a dosage of 30mg/kg in animal level and can be also used for effectively reducing level of serum iron, so that the thiazolidone compound can take hepcidin as a target, can be used for reducing iron level in serum, is hopeful to be a potential medicine used for treating and alleviating iron disorder-related diseases and has a broad clinical application prospect and a great economic development value.

The invention relates to the field of medical science. By detecting the serum iron content in the body of an H7N9 type bird flu patient, it is discovered that decreasing of the serum iron plays the important role in engine body resisting H7N9 bird flu infection, and application of the iron removal drug to preparation of the H7N9 type bird flu prevention and treatment drugs is disclosed through experimental data, theoretical support is provided for prevention and treatment of H7N9 bird flu virus, and particularly basis is provided for research and development of drugs for preventing and treating H7N9 bird flue virus.

The invention discloses therapeutic effect of a ghrelin and L-serine compound on sepsis. Experiments are carried out from an in-vivo level and an in-vitro level. An in-vivo animal model experiment adopts a cecum ligation puncture mouse sepsis model CLP. An in-vitro experiment adopts primary cells corresponding to the small intestine, the liver and the spleen of a mouse. The expression change of iron metabolism related protein in each tissue/cell of a false operation group, a cecum ligation puncture group and a condition of cecum ligation puncture with exogenous ghrelin is observed, the expression of the iron metabolism related protein and the change of cell iron content are observed after the a GHSR1a receptor and MAPK (ErK1/2) signal paths are activated or blocked, changes of serum iron content, erythrocyte generation and tissue iron content of the mouse are monitored, and it is verified that the ghrelin/GHSR1a/MAPK participates in regulation and control of iron mobilization among tissues of a body under a cecum ligation perforation model, increases serum iron, reduces hepcidin, promotes hemoglobin synthesis, and finally relieves sepsis anemia and tissue hypoxia injury.

Compositions containing iron, buffering agent and denatured protein have been prepared that are capable of increasing serum iron in a subject. For example, spray dried microbeads have been prepared containing iron entrapped within a protein matrix and unbound iron in a buffered composition that provides a gastroprotective effect, preserves iron in the more available Fe²⁺ form and improves iron bioavailability in humans relative to previously known vehicles for delivering iron to a subject.

The invention discloses a serum iron ferrous pyrazine colorimetric detection kit, and belongs to the technical field of clinical in vitro detection reagents. The kit is prepared from a reagent R1 and a reagent R2. Buffer solutions of the reagent R1 and the reagent R2 are replaced as 60mM of Tris buffer solution with pH of 4.2, and then a surfactant of the reagent R1 is replaced as TrixtonX-100. The stability of the kit is improved, the linear dependence is better, the accuracy of the reagents are good, and the further popularization and use in the market are benefited.

The invention relates to the medicine of biological medicine, and relates to application of an iron removal drug in the preparation of H7N9 bird flue preventive drugs. The invention discloses application of the iron removal drug in the preparation of H7N9 bird flue preventive drugs. The iron removal drug is deferoxamine; the deferoxamine can be used for preventing and/or curing H7N9 bird flue, that is, the content of serum iron for a patient is reduced by the deferoxamine, so that the effect of preventing H7N9 bird flue is reached.

A non-invasive and minimally-invasive system and method of detecting iron content in nail and hair samples to diagnose iron deficiency anemia. The system comprises a portable and ultra sensitive magnetometer. A sample of hair or nail is collected from the patient and placed in the magnetometer. The magnetometer is sufficiently sensitive to detect or otherwise indicate the iron content of the sample. Diagnosis can be made based on the detected iron level.

Non-invasive and minimally-invasive detection of serum iron in real time. In a method for detecting serum iron content disclosed herein, the method includes positioning a device relative to a nonpigmented epithelial layer covering capillaries of a mammalian subject, operating the device to obtain optical data relating to the capillaries, and determining serum iron content of blood within the capillaries based upon the optical data.

The invention discloses an application of a serum protein marker as a tuberculosis drug resistance diagnosis marker. The serum protein is at least one of a complement protein C4A (C4A), a complement protein C4B (C4B), lactic dehydrogenase B (LDHB), keratinose 9 (KRT9), alpha-2 macroglobulin (A2M), a blood coagulation factor XI (F11), serum iron transferrin (TF), immune globulin alpha-1 (IGHA1), immune globulin (IGHM), immune globulin J chain (JCHAIN), V1-47 proteins (IGLV1-47) and V4-31 proteins (IGHV4-31). According to the application, analysis is carried out according to serum proteins of individuals of different tuberculosis drug resistance types, and a new thought is provided for the targeted therapy of the tuberculosis drug resistance from the angle of the serum proteins.

The invention discloses a kit for detecting ultra-early Parkinson's disease, and belongs to the technical field of biological detection. The kit comprises an alpha-synuclein detection unit, a serum iron detection unit, a serum zinc detection unit, a GSH detection unit, a GSH-Px detection unit and an SOD detection unit. According to the kit, serum alpha-synuclein, metal ions Fe and Zn and GSH, GSH-Px and SOD are detected, related indexes of PD are comprehensively and jointly detected, the kit can be effectively used for auxiliary diagnosis of the ultra-early Parkinson's disease, and the sensitivity and specificity of auxiliary diagnosis are improved. Meanwhile, a required sample is blood, and compared with cerebrospinal fluid extraction and detection, the kit is more convenient and simplerand is more beneficial to clinical popularization.

The invention discloses an application of a traditional Chinese medicine composition in preparation of a medicine for relieving/treating thalassemia. The traditional Chinese medicine composition comprises angelica sinensis, astragalus membranaceus, colla corii asini, leonurus japonicus and pericarpium citri reticulatae. The composition can improve the hematological phenotype of beta thalassemia mice, increase the number of red blood cells, the content of hemoglobin and hematocrit, and reduce the content of serum iron and liver iron; the traditional Chinese medicine composition disclosed by the invention has an obvious relieving/treating effect on the thalassemia, not only widens the adaptation disease range of the components, but also provides a new traditional Chinese medicine formula choice for relieving/treating the thalassemia, and has an obvious application value for relieving/treating the thalassemia.

Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.